Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on June 17, 2022, regarding Tempest Therapeutics, Inc. (TPST), a Delaware corporation. The filing primarily documents the results of the Company's 2022 Annual Meeting of Stockholders and the subsequent approval of amendments to its equity compensation plans.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity plan approvals. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the Company's most recent Form 10-K or 10-Q for financial statements.
Material Changes and Corporate Actions
On June 17, 2022, stockholders approved several material changes to the Company's governance and compensation structures:
- Amended 2019 Equity Incentive Plan (EIP):
- Increased shares available for issuance by 1,132,252 shares.
- Increased the maximum number of incentive stock options to 5,000,000 shares.
- Increased the annual non-employee director compensation limit to $750,000 (from $500,000), effective calendar year 2023.
- Updated change-in-control provisions to accelerate vesting for continuing employees if awards are not assumed by a buyer.
- Amended 2019 Employee Stock Purchase Plan (ESPP):
- Increased shares available for issuance by 107,596 shares.
- Modified the annual share increase calculation (effective Jan 1, 2023) to the lesser of 1.5% of outstanding shares or 500,000 shares.
- Director Election: Geoff Nichol was elected as a Class I director to serve until the 2025 Annual Meeting.
- Auditor Ratification: Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2022.
Guidance, Outlook, and Voting Results
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies beyond the standard incorporation of the proxy statement.
Annual Meeting Voting Summary:
- Attendance: 6,204,072 shares present (approx. 86.49% of the 7,173,094 outstanding shares).
- Proposal 1 (Director Election): Approved (5,447,126 votes for).
- Proposal 2 (Amended EIP): Approved (4,210,293 votes for).
- Proposal 3 (Amended ESPP): Approved (4,460,702 votes for).
- Proposal 4 (Auditor Ratification): Approved (6,179,790 votes for).
- Proposal 5 (Say-on-Pay): Approved (5,284,361 votes for).
- Proposal 6 (Say-on-Pay Frequency): Stockholders voted for an annual frequency (5,301,854 votes for 1 year). Future advisory votes will occur annually until at least 2028.
Investor Verification Checklist
- Verify the full text of the Amended and Restated 2019 Equity Incentive Plan (Exhibit 10.1) and Employee Stock Purchase Plan (Exhibit 10.2) for specific terms not detailed in this summary.
- Review the 2022 Proxy Statement (filed May 2, 2022) for detailed descriptions of the equity plan amendments and executive compensation.
- Confirm the Company's current cash position and burn rate in the most recent quarterly or annual financial report, as this 8-K does not contain liquidity data.
- Note the increased director compensation limit of $750,000 effective 2023 and its potential impact on future operating expenses.